{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 10 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '6.2', 'DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS', '40', '6.2.1', 'Screening and run-in period(s)', '40', '6.2.2', 'Treatment period(s)', '41', '6.2.3', 'Follow up period and trial completion', '42', '7.', 'STATISTICAL METHODS AND DETERMINATION OF', 'SAMPLE SIZE', '44', '7.1', 'STATISTICAL DESIGN - MODEL', '44', '7.2', 'NULL AND ALTERNATIVE HYPOTHESES', '44', '7.3', 'PLANNED ANALYSES', '44', '7.3.1', 'Primary endpoint analyses', '45', '7.3.2', 'Secondary endpoint analyses', '45', '7.3.4', 'Safety analyses', '47', '7.3.5', 'Pharmacokinetic and Pharmacodynamic analyses', '47', '7.4', 'INTERIM ANALYSES', '47', '7.5', 'HANDLING OF MISSING DATA', '48', '7.6', 'RANDOMISATION', '48', '7.7', 'DETERMINATION OF SAMPLE SIZE', '48', '8.', 'INFORMED CONSENT, TRIAL RECORDS, DATA PROTECTION,', 'PUBLICATION POLICY, AND ADMINISTRATIVE STRUCTURE', '49', '8.1', 'TRIAL APPROVAL, PATIENT INFORMATION, INFORMED', 'CONSENT', '49', '8.2', 'DATA QUALITY ASSURANCE', '50', '8.3', 'RECORDS', '50', '8.3.1', 'Source documents', '50', '8.3.2', 'Direct access to source data and documents', '51', '8.3.3', 'Storage period of records', '52', '8.4', 'EXPEDITED REPORTING OF ADVERSE EVENTS', '52', '8.5', 'STATEMENT OF CONFIDENTIALITY AND PATIENT PRIVACY', '52', '8.5.1', 'Collection, storage and future use of biological samples and', 'corresponding data', '52', '8.6', 'TRIAL MILESTONES', '53', '8.7', 'ADMINISTRATIVE STRUCTURE OF THE TRIAL', '53', '9.', 'REFERENCES', '55', '9.1', 'PUBLISHED REFERENCES', '55', '9.2', 'UNPUBLISHED REFERENCES', '56', '10.', 'APPENDICES', '57', '10.1', 'EXERCISE TESTING INCLUDING 6 MINUTE WALK TEST AND', 'WORK CYCLE ERGOMETRY', '57', '10.1.1', 'General considerations for 6MWT and exercise testing', '57', '10.1.2', 'Six-minute walk test', '59', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 11 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '10.2', 'MODIFIED BORG SCALE (MBS-S)', '67', '10.3', \"ST. GEORGE'S RESPIRATORY QUESTIONNAIRE (SGRQ)\", '68', '10.4', 'ELECTRONIC DIARY WITH DAILY PROACTIVE TOOL', '77', '10.4.1', 'The PROactive Tool', '77', '10.4.2', 'Electronic Diary - PROactive Questionnaire', '79', '10.5', 'KBILD', '81', '10.6', 'UCSD MEDICAL CENTER PULMONARY REHABILITATION', 'PROGRAM SHORTNESS-OF-BREATH QUESTIONNAIRE (UCSD-', 'SOBQ)', '84', '10.7', 'LUNG FUNCTION CRITERIA', '89', '11.', 'DESCRIPTION OF GLOBAL AMENDMENT(S)', '90', '11.1', 'GLOBAL AMENDMENT 1', '90', '11.2', 'GLOBAL AMENDMENT 2', '98', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}